Amylyx Pharmaceuticals (AMLX) Enterprise Value: 2021-2025
Historic Enterprise Value for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $867.8 million.
- Amylyx Pharmaceuticals' Enterprise Value rose 6384.82% to $867.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $306.4 million, marking a year-over-year increase of 128.68%. This contributed to the annual value of $82.6 million for FY2024, which is 86.73% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Enterprise Value stood at $867.8 million for Q3 2025, which was up 122.19% from $390.6 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Enterprise Value ranged from a high of $2.1 billion in Q4 2022 and a low of -$180.8 million during Q1 2024.
- Its 3-year average for Enterprise Value is $477.9 million, with a median of $390.6 million in 2025.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Enterprise Value plummeted by 116.89% in 2024 and then spiked by 6,384.82% in 2025.
- Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Enterprise Value stood at $647.4 million in 2021, then skyrocketed by 224.54% to $2.1 billion in 2022, then tumbled by 70.37% to $622.5 million in 2023, then plummeted by 86.73% to $82.6 million in 2024, then skyrocketed by 6,384.82% to $867.8 million in 2025.
- Its Enterprise Value stands at $867.8 million for Q3 2025, versus $390.6 million for Q2 2025 and $109.6 million for Q1 2025.